BMS 3Q Revenues: $4.2 billion (-13%) 3Q Earnings: $338 million (-65%) YTD revenues: $13.7 billion (-3%) YTD Earnings: $1.7 billion (-31%) Comments: Results for the quarter and YTD were negatively impacted by the launch of generic clopidogrel bisulfate (Plavix) and loss of exclusivity of Pravachol. Plavix sales were down 36% and Pravachol sales were down 64% in the quarter. Erbitux, Abilify, Sustiva, Reyataz and Avapro/Avalide and sales of new products Orencia, Baraclude and S...